TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07763418: A Phase 1, Multi-center, Single-dose, Open-label Study to Evaluate the Pharmacokinetics and Safety of Golcadomide (BMS-986369) in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Partic

Sponsor: Bristol-Myers Squibb · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 30 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$3,883,072

Rescue Site Savings

+$2,573,664

Unlock Full NCT07763418 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07763418 Rescue Dossier →